The Saudi Arabia vaccine market was valued at USD 1.14 Billion in 2024, driven by the government initiatives, strategic partnerships, and advancements in healthcare infrastructure in the region. The market is anticipated to grow at a CAGR of 4.90% during the forecast period of 2025-2034, with the values likely to reach USD 1.84 Billion by 2034.

For the third year in a row, the Saudi vaccine market recorded decline in sales value, which decreased by -16.1% to $515M in 2024. In general, consumption, however, recorded a buoyant increase. As a result, consumption reached the peak level of $768M. From 2022 to 2024, the growth of the market remained at a somewhat lower figure.

Saudi Arabia Pediatric Vaccines Market growth is driven by increasing demand for vaccines, government support for immunization programs, and technological advancements in vaccine formulations and delivery systems.

Saudi Arabia Influenza Vaccine Market was valued at USD 44.26 Million in 2024 and is expected to reach USD 53.81 Million by 2030 with a CAGR of 3.51% during the forecast period.

Saudi Arabia Veterinary Vaccines Market is driven by increasing demand for animal-derived food products, rising pet ownership, and advancements in vaccine technology.

The global travel vaccines market, currently valued at approximately $5 billion (2025), is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 8.33% from 2025 to 2033. This expansion is fueled by several key factors. Increasing international travel, particularly among younger demographics and for leisure purposes, creates a larger pool of potential vaccine recipients. Rising awareness of vaccine-preventable diseases and their potential severity, coupled with enhanced public health campaigns emphasizing pre-travel vaccinations, are also significant drivers. Furthermore, the development of novel, more effective, and convenient vaccines, such as combination vaccines offering protection against multiple diseases, is streamlining the vaccination process and boosting market demand. The market's growth is further supported by pharmaceutical companies' continuous research and development efforts focused on improving vaccine efficacy, safety, and delivery systems. However, market growth is not without challenges. Pricing constraints and limited insurance coverage for travel vaccines in some regions could limit accessibility, particularly in developing countries. Moreover, vaccine hesitancy and concerns regarding potential side effects can impact market uptake. Despite these constraints, the expanding global tourism sector and increasing disposable incomes in emerging economies are expected to offset these limitations, resulting in a substantial market expansion over the forecast period. Key players in this market, including Abbott Laboratories, AstraZeneca, CSL, Roche, GSK, Janssen, Pfizer, Qiagen, Sanofi, and Valneva, are constantly innovating and expanding their product portfolios to maintain their competitive edge and capitalize on emerging market opportunities. The market is segmented based on vaccine type, disease targeted, and geographic region, each exhibiting unique growth trajectories influenced by specific demographic and epidemiological factors. Recent developments include: March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases., February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera., May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.. Key drivers for this market are: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Potential restraints include: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Notable trends are: The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period.

In Saudi Arabia Aquaculture Vaccines Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

The Saudi veterinary medicine vaccines market surged to $107M in 2024, rising by 21% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). The market value increased at an average annual rate of +5.3% over the period from 2012 to 2024; however, the trend pattern indicated some noticeable fluctuations being recorded in certain years.

Saudi Arabia Therapeutic Vaccines Market is poised for substantial growth, driven by technological advancements, increasing incidences of chronic diseases.

Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita in Saudi Arabia, 2021 Discover more data with ReportLinker!

Access Middle East Pneumococcal Vaccines Industry Overview which includes Middle East country analysis of (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East), market split by Vaccine Type, Product Type, Sector, Distribution Channel

In Saudi Arabia Vaccine Glass Packaging Market, The routine vaccination segment is expected to remain a primary consumer of vaccine glass packaging.

As per Cognitive Market Research's latest published report, The Global Pertussis Vaccine market was valued at USD 5.06 Billion in 2022 and will reach USD 7.35 Billion by 2030, registering a Compound Annual Growth Rate of 5.47% for the forecast period 2023-2030. The Driving Factor of the Pertussis Vaccine Market

Increasing prevalence of pertussis

Rising prevalence of pertussis globally is expected to drive the market growth over the forecasted period. As per the WHO, over 151,000 pertussis cases were reported worldwide in 2018 and 86% of the worldwide target population received the recommended three doses of the DTP-containing vaccination during infancy as of 2018. Thus, the rising number of pertussis infections across the globe is propelling the growth of the pertussis vaccine market.

The increase in strategic activities by key market players

In order to introduce new goods, major market players are using strategies including partnerships and collaborations; this is anticipated to propel the pertussis vaccine market throughout the course of the projected year. For instance, in June 2021, the French multinational pharmaceutical and healthcare firm Sanofi announced a partnership with the American multinational pharmaceutical business Merck & Co., Inc. to produce vaccines for diseases including Tetanus and diphtheria.

The Restraining Factor of Pertussis Vaccine Market

High cost associated with vaccine developments

The high cost of vaccine development and inadequate access to vaccines in developing countries is the main factor hampering the market growth. For instance, as per the Centers for Disease Control and Prevention (CDC) in July 2023, the cost of Quadracel, a DTaP-IPV vaccine manufactured by Sanofi Pasteur, a vaccines division of the French multinational pharmaceutical company Sanofi, is US$ 61.12 for a single vial. Additionally, new markets provide the captivating potential for the major industry participants in the pertussis vaccine market.

Impact of the COVID-19 pandemic on the Pertussis Vaccine Market:

Since December 2019, the COVID-19 virus pandemic has spread to more than 100 nations, and on January 30, 2020, the World Health Organization proclaimed it to be a public health emergency.

COVID-19 has influenced the economy in three key ways which caused a direct impact on medication, vaccine demand and production, interruptions in the distribution channel, and financial impact on businesses and financial markets. In various nations, including China, India, Saudi Arabia, Egypt, the United Arab Emirates, and others, the transit of medicines and vaccinations from one location to another was challenging due to countrywide lockdowns. Quarantine, travel restrictions and social distancing policies are anticipated to cause a sharp fall in consumer and company expenditure. Additionally, hospitalization delays occurred as fewer patients visited the hospital, which was anticipated to have an impact on the worldwide market for pertussis vaccine. Introduction of Pertussis Vaccine Market

Pertussis is a respiratory disease, usually known as whooping cough, is caused by the bacteria Bordetella pertussis. The major way that pertussis transmits from one person to another is by coughing or sneezing droplets. Infants are especially vulnerable to the disease and it is a major cause of illness and mortality in this age range. Whooping cough is typically treated with the pertussis vaccine. The pertussis vaccine encompasses two main types: whole-cell vaccines and acellular vaccines. This vaccination is only accessible when combined with other immunizations. The Pertussis Vaccine is the most reliable and economical means of maintaining a pertussis-free environment. The World Health Organization has included the tetanus vaccine on the list of essential medicines because it has helped reduce the prevalence of tetanus in the US by 95% since it was first introduced in 1924.

The size of the GCC Animal Health Market market was valued at USD 1.37 billion in 2023 and is projected to reach USD 2.58 billion by 2032, with an expected CAGR of 9.45 % during the forecast period. GCC animal health market is the market of services that are associated with the health and welfare of the animals in the member countries of the Gulf Cooperation Council which include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, & UAE. Some of the products that fall under this market are; vaccines, antiretroviral drugs, diagnostic tools, and feed supplements for livestock, poultry, and pets. Disease prevention, treatment and control being the major use is followed by increased animal productivity and food security especially in livestock production. Trends observed in the current world indicate that more and more people are adopting pets and therefore the need for their care and better health, while in the cases of livestock, issues of food security call for the improvement of their health and reproduction. New innovations in diagnose, preventions through vaccination, hyper-filtration in feeds, growth in governmental support for Veterinary infrastructure are helping the market growth. Recent developments include: In February 2024, EQT investment firm acquired Dechra Pharmaceuticals. , In February 2024, Merck Animal Health signed a definitive agreement to acquire Elanco Animal Health's Aqua business. , In May 2023, Zoetis received FDA approval for Librela, which has application in Osteoarthritis (OA) pain , In August 2023, TVG & Australia-based Troy Animal Healthcare extended their product distribution partnership to provide affordable pharmaceuticals for animal care in the GCC region. , In October 2023, Animal Health Directorate of Bahrain launched vaccination programs against foot-and-mouth disease & smallpox in animals. .

MARKET SIZE AND GROWTH The Middle East and Africa (MEA) pharmaceutical plastic bottles market was valued at USD 0.74 billion in 2025 and is projected to reach USD 1.12 billion by 2033, exhibiting a CAGR of 3.76%. The rise in pharmaceutical consumption, growing prevalence of chronic diseases, and increasing demand for safe and convenient packaging solutions are key drivers of the market. The region is witnessing a surge in the production and consumption of pharmaceuticals, including both generic and branded drugs, due to the rising population and increasing accessibility to healthcare services. COMPETITIVE LANDSCAPE AND KEY TRENDS Key players in the MEA pharmaceutical plastic bottles market include Amcor Group GmbH, Berry Global Inc, AptarGroup Inc, Gil Plastic Products Ltd, ALPLA Werke Alwin Lehner GmbH & Co KG, Silgan Holdings Inc, AL AMANA PLASTICS, B & I Polycontainers (Pty) Ltd, and Saudi Basic Industries Corporation. Leading companies are focusing on innovation and product development to cater to the evolving needs of the pharmaceutical industry. Trends such as the adoption of bioplastics and sustainable packaging solutions, the use of smart packaging technologies, and the integration of digital printing are gaining traction in the market. Additionally, the increasing adoption of e-commerce platforms for pharmaceutical sales is driving the demand for convenient and tamper-proof packaging solutions for online deliveries. Recent developments include: May 2024: Berry Global Group Inc., a prominent player in designing, developing, and manufacturing patient-centric healthcare solutions, bolstered its healthcare production capacity by investing in new assets and manufacturing capabilities, aiming for a significant 30% increase., June 2023 - Lifera, a Saudi Arabian biopharmaceutical company, and Sanofi, a global player in vaccine development, partnered with Arabio and signed a Memorandum of Understanding (MOU). The primary goal of this agreement is to enhance the domestic production of vaccines in Saudi Arabia. The partnership with global player Sanofi ensures that the vaccines produced adhere to high-quality standards. This will likely extend to the packaging materials, including plastic bottles, driving demand for high-quality, compliant pharmaceutical packaging solutions in the region., January 2023: Niner Pharmaceuticals LLC, a pharmaceutical firm established in the UAE, announced plans to create a complete supply chain between the Indian and Middle Eastern markets. The business is building advanced manufacturing facilities in India to achieve this goal. International agencies for pharmaceutical products, such as the USFDA, EU, and UK MHRA, will certify these production facilities. The company is expected to increase its operations this way and satisfy the rising demand in the Middle Eastern markets.. Key drivers for this market are: Development of Modern and Improved Healthcare Infrastructure, Adoption of Recyclable and Eco-Friendly Plastic Bottles in Response to Growing Environmental Awareness. Potential restraints include: Development of Modern and Improved Healthcare Infrastructure, Adoption of Recyclable and Eco-Friendly Plastic Bottles in Response to Growing Environmental Awareness. Notable trends are: Polyethylene Terephthalate (PET) is Expected to Witness Significant Growth.